Space 519 Aims to Be More Than a Luxury Store
There is fashion; dining, with three options ranging from grab-and-go to full service; home decor; gifts; fine jewelry, and apothecary, all in one mini-department store.
More from WWD
LuisaViaRoma Files for Protection Measures With Florence Court, Italian Chamber of Commerce
Passing Grades for Back-to-school Shopping
Hailey Bieber Preps Rhode for Sephora Debut
'You can't replicate this online,' Lance Lawson said during a walk-through of the 6,000-square-foot space located at the 1920s-era Spanish-style outdoor mall. Lawson owns Space 519 with his husband Jim Wetzel. 'If there was a website trying to sell you our favorite Swedish fish and a Khaite purse, you'd be like, 'What?''
Space 519 was among the first retailers WS Development, owner of the 100,000-square-foot Plaza del Lago, approached about the project. Located at the southwest corner of the mall with views of Lake Michigan, the store's neighbors are Jenni Kayne and Rag & Bone. James Perse has also opened. According to a mall sidewalk sign, Hermès, Oscar de la Renta, LoveShackFancy, Cynthia Rowley, Hill House Home, La Vie Style House, Peter Millar, Studs, Pilatesville and Veronica Beard are 'coming soon.'
'The first space they presented us had the restaurant on the second floor and we're like, 'no, the restaurant has to be on the first floor,'' Lawson said. 'When it's full and you hear the glasses clinking and the people laughing, the store feels very alive.'
Women's clothing is the backbone of the business, but food and dining remain the 'secret sauce,' Lawson noted. The owners introduced dining at their Gold Coast location in 2018 and found it's a draw. Like that store, Plaza del Lago features The Lunchbox, located immediately upon entering, with coffee drinks and grab-and-go items, and The Lunchroom, a full-service, 50-seat capacity restaurant serving breakfast, lunch and brunch. New to the store is The Lago Room, a 40-seat, European-style café serving cocktails and wine.
'Everyone that dines does not shop,' added Lawson, noting that the Cowboy Cookies sold at The Lunchbox are his mother's recipe. 'The food is strong enough that many people come here just to eat.'
The retail owners oversaw the entire project, including the decision to remove drop ceilings to uncover a skylight, tear down walls and install more windows. The center of the store is what Lawson and Wetzel call 'happy modern,' with track lighting and midcentury pieces such as a reworked 1950s Drexel sofa. Luxe collectibles, such as Fornasetti plates, are situated near oversize coffee table books.
There is art throughout, including a 10-foot mural by local Winnetka artist Paige Spearin, who designed prints for Lilly Pulitzer, an oversize piece by Maggie Meiners, also from Winnetka, and a photography piece by Nick Mele.
'People are coming here for all of it,' Lawson said. 'They want to participate in the food, the styling, the broad range of price points. By having all those components, we can be a true destination.'
The store features ready-to-wear from Jil Sander, Missoni, Proenza Schouler and Tibi. Exclusive apparel lines include Khaite, Thom Browne, Partow and Italian knitwear label Sasuphi. Accessory collections include Metier, Valextra and Savette. The store is about to launch a residency with Nak Armstrong, a CFDA Award-winning fine jewelry designer. Other key jewelry brands include ByPariah, Lizzie Fortunato and Gabriela Artigas. Apothecary brands include Vintner's Daughter, Augustinus Bader, D.S. & Durga and Dr. Few Skincare.
Prices range from $6.95 for a greeting card to $295 for a Lou Lou de Saison silk sleeveless blouse to $3,995 for a Khaite leather jacket.
While the luxury market faces global declines, Lawson said their business has grown 20 percent year over year.
'Since the pandemic, we've really hit our stride,' he said. 'Barneys closing in Chicago has been a catalyst for us. People loved the DNA of Barneys and we love being able to replicate that on a smaller scale.'
The owners strategically stagger their orders so there's newness at all times. They also feature limited units in each size.
'That's something our clients always talk about,' Lawson said. 'So it's new, it's not on sale. So you know if you don't buy it, it's going to be gone.'
Lawson said their goal is to increase business for both stores from the high single-digit millions to double-digit millions for the first year. Of that goal, the Plaza del Lago store is projected to do 25 percent less than the Gold Coast store during the first year.
'We're profitable,' said Lawson, noting they buy almost entirely in season.
The real issue is the devaluation of the dollar, he said.
'When [President Joe] Biden left, it was 1.03, yesterday I did a trade and it was at 1.175. That's 14 percent more just in currency conversion because we buy a lot from Europe that we pay for in euros. Then you add for Europe 10 percent in tariffs. It's terrible,' Lawson said. 'At the end of the day it's a tax. We run on a 10 percent margin in the very best circumstances.'
Wetzel said a big reason for their success is their sales associates, who lean in on Midwest nice. If Barneys is the store's aspirational DNA, the TV show 'Cheers' is the vibe.
'It's like going back to your favorite restaurant all the time,' Wetzel said. 'You know what you're going to order. You love that salad. You know that martini is going to be super cold. That's why you keep going back.'
Best of WWD
Macy's Is Closing 66 Stores in 2025 — Here's the List, Live Updates
Inside the Demise of Lord & Taylor
COVID-19 Spikes Elevate Retail Concerns
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Xiaomi targets entry into European EV market in 2027
China's Xiaomi Corporation has revealed ambitions to break into the European electric vehicle (EV) market by 2027. This announcement comes on the heels of the company's foray into the EV sector within China, which has seen significant growth over the past year. Xiaomi provided insights into the company's expansion strategy following a notable 30.5% increase in overall quarterly revenue during the June quarter, reaching 116bn yuan ($16.2bn). Its financial report indicated that the company's smart EV, AI, and other initiatives produced 21.3bn yuan in revenue in the second quarter (Q2) 2025. Xiaomi's vehicle deliveries for Q2 2025 stood at 81,302 units, representing a 197.7% year-on-year (YoY) growth compared to the same period in the previous year. The company's network of EV sales centres has also expanded, with 335 locations now spread across 92 cities, and a net addition of 100 sales centres quarter over quarter. The EV division's losses have narrowed to approximately 300m yuan during the quarter. Additionally, the gross margin for Xiaomi's businesses, which includes smart EVs and AI, improved to 26.4% in Q2, up from 15.4% in the previous year period. According to data from the China Association of Automobile Manufacturers (CAAM), sales of Chinese-made vehicles, including exports, experienced a near 15% YoY increase to 2.593 million units in July 2025. This comes after a 5% decline to 2.262 million units the year before. Domestic sales saw a 13% rise to 2.018 million units, while exports surged by 23% to 575,000 units. In June, Xiaomi launched the YU7, its first battery-powered SUV model. The launch was a significant event for Xiaomi's automotive business, with local reports indicating that the automaker received over 200,000 confirmed orders for the new model within an hour of its unveiling. Furthermore, in the same month, Xiaomi secured a 50-year lease for a 485,134m2 plot of land in Beijing, China, for smart connected car and components projects. The Beijing municipal planning and natural resources commission announced the deal, valued at 635m yuan ($88m). In March, Xiaomi agreed to raise $5.5bn through a placement and subscription agreement involving the sale and issuance of 800 million shares. "Xiaomi targets entry into European EV market in 2027" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
35 minutes ago
- Business Wire
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). This enforcement action targets Pfizer's activities in the 18 countries of the European Union that are presently participating in the UPC. The European Patent Office's recent grant of the '265 Patent to Enanta was published in the European Patent Bulletin today. The '265 Patent is based on Enanta's July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists. The '265 Patent is the European counterpart of U.S. Patent No. 11,358,953 (the '953 Patent) involved in ongoing U.S. litigation between Enanta and Pfizer Inc. Under UPC procedures, a hearing on the infringement action is expected to occur within the UPC's published 12-month target, with the decision rendered within weeks thereafter. If the UPC determines there has been infringement, subsequent proceedings would be required to determine damages. All timelines remain subject to potential rights of appeal and other customary proceedings in European patent litigation. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET ® (U.S.) and MAVIRET ® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. Forward Looking Statements Disclaimer This press release contains forward-looking statements, including statements with respect to Enanta's filing in the UPC of a suit against Pfizer Inc. and certain of its subsidiaries seeking a determination of liability for use and infringement of Enanta's patent and Enanta's expectations with respect to any further action with respect to such proceedings. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including those covering one or more of its product candidates, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta's senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta's reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in 'Risk Factors' in Enanta's Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.


CNBC
36 minutes ago
- CNBC
Why is the UK struggling with inflation, compared to the euro zone?
Florian IeIpo, head of macro at Lombard Odier Investment Managers, discuss sticky inflation in the U.K. and why the situation is different on the European continent.